Biomarker for diagnosing VEO-IBD and IL10RA mutant enteritis
Through biomarkers and 16s RNA gene sequencing of bacteria such as Bacteroides, Bifidobacterium, and combined with artificial intelligence, a diagnostic model of VEO-IBD and IL10RA mutations was constructed, solving the problems of high diagnostic screening thresholds and misdiagnosis in the existing technology. Achieve efficient and non-invasive diagnostic effects.
Patent Information
- Application Number
- CN202410954685.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art has problems with high detection and screening thresholds, high invasive examination risks, frequent misdiagnosis and misdiagnosis in the diagnosis of extremely early-onset inflammatory bowel disease (VEO-IBD) and IL10RA mutant enteritis, and lacks specific diagnostic markers.
Using biomarkers of bacteria such as Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus and Veillonella, a diagnostic model was constructed through 16s RNA gene sequencing and artificial intelligence machine learning, and using fecal bacterial abundance and composition differentiation to identify VEO-IBD and IL10RA mutation.
Accurate diagnosis of VEO-IBD and IL10RA mutations is achieved, which improves diagnostic sensitivity and specificity, reduces the risk of invasive examinations, and provides a non-invasive screening method.
Smart Images

Figure CN118910292A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and particularly relates to a biomarker for diagnosing VEO-IBD and IL10RA mutant enteritis. Background Art
[0002] Inflammatory bowel disease (IBD) refers to a group of nonspecific chronic gastrointestinal inflammatory diseases of unknown cause, including Crohn's disease (CD), ulcerative colitis (UC) and unclassified IBD (IBD-U). Children with IBD under the age of 6 have their own unique phenotype. This type of IBD is defined as very early onset IBD (VEO-IBD). Their intestinal lesions are more severe, the stenosis rate is increased, the systemic symptoms are obvious, and the growth and development are seriously affected. The quality of life is greatly damaged and a significant burden is placed on the health care system. At present, the detection and diagnosis of IBD mainly rely on serological related tests, digestive endoscopy, intestinal biopsy pathology and genetic examination. Some patients may need repeated endoscopic examinations and genetic testing to confirm the diagnosis. Since blood tests, endoscopy and other examinations are invasive and intrusive, there are problems and difficulties in carrying out screening tests in children, especially infants, such as high thresholds, certain risks and poor medical compliance. At the same time, due to the lack of specific diagnostic markers, misdiagnosis and missed diagnosis are prone to occur.
[0003] The latest research shows that IBD may be caused by an inappropriate and persistent inflammatory response of a genetically susceptible host to intestinal microorganisms, and is related to the active or passive interaction between intestinal microorganisms and the immune system. There are hundreds of millions of microorganisms in the human intestine, which make up the intestinal microbiota, and play an important role in maintaining intestinal homeostasis and regulating host metabolism and immunity. Exploratory studies on mouse models of inflammatory bowel disease also suggest that intestinal microorganisms are closely related to the occurrence of the disease and may be one of the important driving factors for the occurrence and development of the disease. The characteristics and functions of the intestinal microbiota are crucial for the development of new IBD screening, diagnosis and treatment strategies. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a biomarker for diagnosing VEO-IBD and IL10RA mutation enteritis.
[0005] VEO-IBD is very early-onset IBD; LO-IBD is late-onset IBD. PIBD is all childhood-onset IBD.
[0006] The present invention discloses an application of a biomarker in the preparation of a product for diagnosing or screening VEO-IBD, wherein the biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
[0007] The present invention discloses a reagent for detecting biomarkers for use in preparing a product for diagnosing or screening VEO-IBD. The biomarker is one or more of the genera Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella. For example, when the relative abundance of Bifidobacterium in the intestinal flora is less than 0.2844%, VEO-IBD can be considered for diagnosis.
[0008] The present invention provides an application of a biomarker in the preparation of a product for diagnosing or screening LO-IBD, wherein the biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
[0009] The present invention discloses a reagent for detecting biomarkers for use in preparing a product for diagnosing or screening LO-IBD. The biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella. For example, when the relative abundance of Bifidobacterium in the intestinal flora of an IBD patient is less than 2.1295%, LO-IBD may be considered.
[0010] The present invention relates to an application of a biomarker in the preparation of a product for diagnosing or screening PIBD, wherein the biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
[0011] The present invention discloses a reagent for detecting biomarkers for use in preparing a product for diagnosing or screening PIBD. The biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella. For example, when the relative abundance of Bifidobacterium in the intestinal flora is less than 0.7636%, PIBD can be considered for diagnosis.
[0012] The invention discloses an application of a biomarker in preparing a product for diagnosing or identifying whether IL10RA is mutated in VEO-IBD, wherein the biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus and Veillonella.
[0013] The present invention discloses a reagent for detecting biomarkers for use in preparing a product for diagnosing or identifying whether IL10RA is mutated in VEO-IBD. The biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella. For example, when the relative abundance of Enterococcus in the intestinal flora is greater than 0.9465%, IL10RA mutation VEO-IBD can be considered for diagnosis.
[0014] The present invention provides an application of a biomarker in preparing a product for diagnosing or distinguishing VEO-IBD and LO-IBD, wherein the biomarker is one or more of the genera Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
[0015] The present invention provides an application of a reagent for detecting a biomarker in preparing a product for diagnosing or distinguishing VEO-IBD and LO-IBD, wherein the biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella. For example, when the relative abundance of Bacteroides in the intestinal flora is greater than 0.1474%, LO-IBD can be considered for diagnosis.
[0016] The biomarkers are Bifidobacterium, Bacteroides, and Enterococcus.
[0017] The reagent for detecting biomarkers is a reagent for detecting biomarkers in fecal flora.
[0018] The present invention starts from the changes in the intestinal microbiome of children with VEO-IBD in inflammatory bowel disease, analyzes the correlation between changes in VEO-IBD and specific microorganisms related to IBD, analyzes and detects the abundance and composition of the intestinal flora, constructs a VEO-IBD detection model, and uses artificial intelligence machine learning to find and optimize intestinal flora markers that distinguish VEO-IBD.
[0019] Beneficial Effects
[0020] The five most differentiated genera in the intestinal flora of three types of samples (VEO-IBD, LO-IBD, HC) were constructed as indicators of binomial logistic regression analysis to establish a diagnostic model. ROC curve analysis was used to evaluate the differential flora, and it was found that the differentiation of flora had diagnostic value. Among them, Bifidobacterium in the diagnostic model of the VEO-IBD group and the healthy children group showed good diagnostic value, with an AUC value of 0.91 (95% CI: 0.82-1.0). When the cutoff value was 0.2844%, the sensitivity was 84% and the specificity was 87% ( Figure 3A), indicating that the differentiation of Bifidobacterium can be used as a marker flora in the bacterial diagnosis model. The Bifidobacterium in the diagnostic model of the LO-IBD group and the healthy children group showed good diagnostic value, with an AUC value of 0.85 (95% CI: 0.72-0.97). When the cutoff value was 2.1295%, the sensitivity was 84% and the specificity was 73% ( Figure 3 B), indicating that the differentiation of Bifidobacterium can be used as a marker flora in the bacterial diagnosis model. The Bifidobacterium in the diagnostic model of the PIBD group and the healthy children group showed good diagnostic value, with an AUC value of 0.88 (95% CI: 0.78-0.97). When the cutoff value was 0.7636%, the sensitivity was 83% and the specificity was 80% ( Figure 3 C), indicating that the differentiation of Bifidobacterium can be used as a marker flora in the genus diagnostic model. The Bacteroidetes in the VEO-IBD group and LO-IBD diagnostic model showed good diagnostic value. The AUC value was 0.76 (95% CI: 0.64-0.88), and when the cutoff value was 0.1474%, the sensitivity was 69% and the specificity was 78%. ( Figure 3 E). The above results indicate that genus-based biomarkers have good diagnostic and predictive effects on VEO-IBD.
[0021] The five most differentiated bacterial genera in the intestinal flora of the two types of samples (IL10RA group and non-IL10RA group) were constructed as indicators of binomial logistic regression analysis to establish a diagnostic model. ROC curve analysis was used to evaluate the differential flora, and it was found that the differentiation of flora had diagnostic value. Enterococci in the diagnostic model of the IL10RA group and the non-IL10RA control group showed good diagnostic value, with an AUC value of 0.79 (95% CI: 0.63-0.95). When the cutoff value was 0.9465%, the sensitivity was 0.94% and the specificity was 0.56% ( Figure 3 D). BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1Diversity of intestinal microbiota; Shannon index of intestinal microbiota in three groups (VEOIBD, LO-IBD, HC) (A); Shannon index of intestinal microbiota in two groups (IL10RA, control) (B). Simpson index of intestinal microbiota in three groups (VEOIBD, LO-IBD, HC) (C). Simpson index of intestinal microbiota in two groups (IL10RA, control) (D). PcoA plot of unweighted unit distance of community structure of intestinal microbial units in three groups (E). PcoA plot of unweighted unit distance of community structure of intestinal microbial units in two groups (F). VEOIBD: very early-onset IBD group, IBD: late-onset IBD group, HC: healthy children group, control: non-IL10RA mutation group in VEOIBD.
[0023] Figure 2 Analysis of the structure and relative abundance of the intestinal microbiota. The composition ratio of intestinal microbes in the three groups (A). The composition ratio of intestinal microbes in the two groups (B). Comparison of the changes of the five most variable intestinal microbes in the three groups of VEOIBD, LO-IBD, and HC (C). The top three bacterial species that caused the most ecological imbalance in the two groups of IL10RA mutation group and non-IL10RA mutation group in VEOIBD (D).
[0024] Figure 3 Receiver operating characteristic (ROC) curve analysis of diagnostic indicators. The main bacterial flora that can be used to distinguish between VEO-IBD and healthy children (A). The main bacterial flora that can be used to distinguish between LO-IBD and healthy children (B). The main bacterial flora that can be used to distinguish between PIBD and healthy children (C). The main bacterial flora that can be used to distinguish between the L10RA mutation group and the non-IL10RA mutation group (D). The main bacterial flora that can be used to distinguish between VEO-IBD and LO-IBD (E). DETAILED DESCRIPTION
[0025] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.
[0026] 16s RNA gene sequencing and data analysis
[0027] according to Total DNA was extracted according to the instructions of soil kit (Omega Bio-tek, Norcross, GA, US). The DNA concentration and purity were detected by NanoDrop2000, and the quality of DNA extraction was detected by 1% agarose gel electrophoresis; 338F (5'-ACTCCTACGGGAGGCAGCAG-3'), as shown in SEQ ID NO.1 and 806R (5'-GGACTACHVGGGTWTCTAAT-3') as shown in SEQ ID NO.2 were used. The primers for V3-V4 variable region were PCR amplified, and the purified amplified fragments were constructed into PE 2*300 library according to the standard operating procedures of Illumina MiSeq platform (Illumina, San Diego, USA). Finally, the Miseq PE300 platform of Illumina was used for sequencing (Shanghai Meiji Biomedical Technology Co., Ltd.).
[0028] In-depth analysis of sequencing data included: α-diversity index and β-diversity were calculated using unweighted unifrac distance and visualized by principal coordinate analysis (PCoA) using the open online tool Majorbio platform. R language heatmap package, pROC package and ggplot2 package were used for correlation analysis and receiver operating characteristic (ROC) analysis to evaluate the diagnostic value of identification indicators and build screening models.
[0029] Example 1
[0030] The study subjects were children with VEO-IBD, IBD (late-onset IBD, LO-IBD) and healthy children in Ruijin Hospital Affiliated to Shanghai Jiao Tong University. Fecal specimens were collected from patients, 16 rRNA tests were performed, and data analysis was performed on the Majorbio cloud platform. A total of 79 children's fecal samples were included, including 32 cases of VEO-IBD, 32 cases of late-onset IBD (LO-IBD) and 15 healthy children.
[0031] The study found that the diversity analysis of the microbiota showed that the diversity of intestinal microorganisms in children with VEO-IBD and IBD was significantly reduced compared with that in healthy children, with the Shannon index being 1.94±0.90, 2.35±0.54, and 2.66±0.50, respectively. Figure 1 A). Among them, the microbial diversity of children with IL10RA mutation VEO-IBD was further reduced, with Shannon index of 1.60±0.90 and 2.29±0.79 ( Figure 1B) The changes in the Simpson index showed a consistent trend, with VEO-IBD having the lowest microbial diversity and the microbial diversity of children with IL10RA mutations further reduced ( Figure 1 CD). Beta diversity, measured by the unweighted distance of OTU community structure, showed that the microbiota of the healthy group was more closely clustered and the microbial profiles were more similar, while the microbial profiles of children with IBD were changed ( Figure 1 E).
[0032] Further analysis of the fecal microbiota revealed that the abundance of Bacteroidetes and Actinobacteria was significantly reduced in VEO-IBD ( Figure 2 A), the proportion of Bacteroidetes in children with IL10RA mutation was further reduced ( Figure 2 B). The abundance changes of Bifidobacterium and Bacteroides were at the forefront of the differences among VEO-IBD, LO-IBD and HC ( Figure 2 C). Enterococcus is the main bacterial genus with different IL10RA mutations ( Figure 2 D).
[0033] The five most differentiated genera in the intestinal flora of three types of samples (VEO-IBD, LO-IBD, HC) were constructed as indicators of binomial logistic regression analysis to establish a diagnostic model. ROC curve analysis was used to evaluate the differential flora, and it was found that the differentiation of flora had diagnostic value. Among them, Bifidobacterium in the diagnostic model of the VEO-IBD group and the healthy children group showed good diagnostic value, with an AUC value of 0.91 (95% CI: 0.82-1.0). When the cutoff value was 0.2844%, the sensitivity was 84% and the specificity was 87% ( Figure 3 A), indicating that the differentiation of Bifidobacterium can be used as a marker flora in the bacterial diagnosis model. The Bifidobacterium in the diagnostic model of the LO-IBD group and the healthy children group showed good diagnostic value, with an AUC value of 0.85 (95% CI: 0.72-0.97). When the cutoff value was 2.1295%, the sensitivity was 84% and the specificity was 73% ( Figure 3 B), indicating that the differentiation of Bifidobacterium can be used as a marker flora in the bacterial diagnosis model. The Bifidobacterium in the diagnostic model of the PIBD group and the healthy children group showed good diagnostic value, with an AUC value of 0.88 (95% CI: 0.78-0.97). When the cutoff value was 0.7636%, the sensitivity was 83% and the specificity was 80% ( Figure 3C), indicating that the differentiation of Bifidobacterium can be used as a marker flora in the genus diagnostic model. The Bacteroidetes in the VEO-IBD group and LO-IBD diagnostic model showed good diagnostic value. The AUC value was 0.76 (95% CI: 0.64-0.88), and when the cutoff value was 0.1474%, the sensitivity was 69% and the specificity was 78%. ( Figure 3 E). The above results indicate that genus-based biomarkers have good diagnostic and predictive effects on VEO-IBD.
[0034] The five most differentiated bacterial genera in the intestinal flora of the two types of samples (IL10RA group and non-IL10RA group) were constructed as indicators of binomial logistic regression analysis to establish a diagnostic model. ROC curve analysis was used to evaluate the differential flora, and it was found that the differentiation of flora had diagnostic value. Enterococci in the diagnostic model of the IL10RA group and the non-IL10RA control group showed good diagnostic value, with an AUC value of 0.79 (95% CI: 0.63-0.95). When the cutoff value was 0.9465%, the sensitivity was 0.94% and the specificity was 0.56% ( Figure 3 D).
[0035] Table 1 Cutoff values and corresponding parameters of each group of diagnostic and differential diagnostic markers
[0036]
Claims
1. Use of a biomarker in the preparation of a product for diagnosing or screening VEO-IBD, characterized in that: The biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
2. Use of a reagent for detecting biomarkers in the preparation of a product for diagnosing or screening VEO-IBD, characterized in that: The biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
3. Use of a biomarker in the preparation of a product for diagnosing or screening LO-IBD, characterized in that: The biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
4. Use of a reagent for detecting a biomarker in the preparation of a product for diagnosing or screening LO-IBD, characterized in that: The biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
5. Use of a biomarker in the preparation of a product for diagnosing or identifying PIBD, characterized in that: The biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
6. Use of a reagent for detecting a biomarker in the preparation of a product for diagnosing or identifying PIBD, characterized in that: The biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
7. Use of a biomarker in the preparation of a product for diagnosing or identifying whether IL10RA is mutated in VEO-IBD, characterized in that: The biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
8. Use of a reagent for detecting a biomarker in the preparation of a product for diagnosing or identifying whether IL10RA is mutated in VEO-IBD, characterized in that: The biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
9. Use of a biomarker in the preparation of a product for diagnosing or distinguishing VEO-IBD and LO-IBD, characterized in that: The biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
10. Use of a reagent for detecting biomarkers in the preparation of a product for diagnosing or distinguishing VEO-IBD and LO-IBD, characterized in that: The biomarker is one or more of Bacteroides, Bifidobacterium, Escherichia-Shigella, Enterococcus, and Veillonella.
11. The use according to any one of claims 1 to 10, characterized in that: The biomarkers are Bifidobacterium, Bacteroides, and Enterococcus.
12. The use according to claim 2, 4, 6, 8 or 10, characterized in that: The reagent for detecting biomarkers is a reagent for detecting biomarkers in fecal flora.
Citation Information
Cited By
Wehononella enteritidis and application thereof
CN119331783A
